Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1β synthesis by human neutrophils

European Respiratory Journal

Volumn 37, Issue 2, 2011, Pages 406-415

  Langereis, J D ^a   Oudijk, E J D ^a   Schweizer, R C ^a   Lammers, J W J ^a   Koenderman, L ^a   Ulfman, L H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Glucocorticosteroids; Interleukin 1 receptor antagonist; Interleukin 1 ; Neutrophil

Indexed keywords

BUDESONIDE; CICLESONIDE; DEXAMETHASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION;

AGED; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DEXAMETHASONE; ENDOTHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953658289     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00170409     Document Type: Article

References (66)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
2. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 2: CD002991.
3. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721. (Pubitemid 39140629)
4. Peleman RA, Rytila PH, Kips JC, et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 839-843. (Pubitemid 29234788)
5. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285. (Pubitemid 28489033)
6. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006; 7: 675-681. (Pubitemid 43827263)
7. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: Suppl. 34, 50s-59s.
8. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest 2007; 131: 37-43. (Pubitemid 46122972)
9. Man SF, Xuekui Z, Vessey R, et al. The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study. Ther Adv Respir Dis 2009; 3: 73-80.
10. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-1214. (Pubitemid 351860929)
11. Pujols L, Mullol J, Roca-Ferrer J, et al. Expression of glucocorticoid receptor α- and β-isoforms in human cells and tissues. Am J Physiol Cell Physiol 2002; 283: C1324-C1331.
12. Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71. (Pubitemid 34027951)
13. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990; 62: 1205-1215.
14. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-κB activation and function by glucocorticoids. J Mol Endocrinol 2002; 28: 69-78. (Pubitemid 34428757)
15. Caldenhoven E, Liden J, Wissink S, et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995; 9: 401-412.
16. Bamberger CM, Bamberger AM, de Castro M, et al. Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
17. Pujols L, Mullol J, Picado C. α and β glucocorticoid receptors: relevance in airway diseases. Curr Allergy Asthma Rep 2007; 7: 93-99. (Pubitemid 46744744)
18. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426. (Pubitemid 43185854)
19. Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 2004; 1: 222-230.
20. Shieh JH, Peterson RH, Moore MA. Cytokines and dexamethasone modulation of IL-1 receptors on human neutrophils in vitro. J Immunol 1993; 150: 3515-3524. (Pubitemid 23129732)
21. Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995; 86: 3181-3188.
22. Sivertson KL, Seeds MC, Long DL, et al. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils. Cell Immunol 2007; 246: 34-45. (Pubitemid 47087769)
23. Dale DC, Fauci AS, Guerry DI, et al. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 1975; 56: 808-813.
24. Saffar AS, Dragon S, Ezzati P, et al. Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils. J Allergy Clin Immunol 2008; 121: 492-498 e410.
25. ten Hove W, Houben LA, Raaijmakers JA, et al. Rapid selective priming of FcαR on eosinophils by corticosteroids. J Immunol 2006; 177: 6108-6114.
26. Schleimer RP, Freeland HS, Peters SP, et al. An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther 1989; 250: 598-605. (Pubitemid 19216145)
27. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. www.goldcopd.com Date last updated: November 2008.
28. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009; 43: 519-527.
29. Schweizer RC, van Kessel-Welmers BA, Warringa RA, et al. Mechanisms involved in eosinophil migration. Platelet-activating factor-induced chemotaxis and interleukin-5-induced chemokinesis are mediated by different signals. J Leukoc Biol 1996; 59: 347-356.
30. Chasserot-Golaz S, Beck G. An approach to the mechanism of the potent antiglucocorticoid: 17 β-hydroxy-11 β-4-dimethylaminophenyl-17 α-propynyl-estra-4,9-dien-3-one. J Steroid Biochem1984; 21: 585-591.
31. Furlaneto CJ, Campa A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-1β, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 2000; 268: 405-408. (Pubitemid 30119635)
32. McColl SR, Paquin R, Menard C, et al. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 1992; 176: 593-598.
33. Schröder AK, von der Ohe M, Kolling U, et al. Polymorphonuclear leucocytes selectively produce anti-inflammatory interleukin-1 receptor antagonist and chemokines, but fail to produce proinflammatory mediators. Immunology 2006; 119: 317-327. (Pubitemid 44571049)
34. Marie C, Pitton C, Fitting C, et al. IL-10 and IL-4 synergize with TNF-α to induce IL-1ra production by human neutrophils. Cytokine 1996; 8: 147-151. (Pubitemid 26109153)
35. Malyak M, Smith MF Jr, Abel AA, et al. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 β. J Clin Immunol 1994; 14: 20-30. (Pubitemid 24071697)
36. Brooks CJ, King WJ, Radford DJ, et al. IL-1β production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol 1996; 106: 273-279. (Pubitemid 26359893)
37. Marucha PT, Zeff RA, Kreutzer DL. Cytokine regulation of IL-1 β gene expression in the human polymorphonuclear leukocyte. J Immunol 1990; 145: 2932-2937. (Pubitemid 20382563)
38. Takahashi GW, Andrews DF 3rd, Lilly MB, et al. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood 1993; 81: 357-364. (Pubitemid 23027151)
39. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: 1453-1455. (Pubitemid 24356667)
40. Pitsiou G, Kyriazis G, Hatzizisi O, et al. Tumor necrosis factor-α serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med 2002; 96: 594-598.
41. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-1022.
42. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
43. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008; 132: 344-362.
44. Altstaedt J, Kirchner H, Rink L. Cytokine production of neutrophils is limited to interleukin-8. Immunology 1996; 89: 563-568. (Pubitemid 26419658)
45. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842. (Pubitemid 39389622)
46. Stanczyk J, Kowalski ML, Grzegorczyk J, et al. RANTES and chemotactic activity in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Mediators Inflamm 2005; 6: 343-348. (Pubitemid 41803403)
47. Gabay C, Smith MF, Eidlen D, et al. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930-2940. (Pubitemid 27278670)
48. Hiscott J,Marois J, Garoufalis J, et al. Characterization of a functional NF-κB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993; 13: 6231-6240. (Pubitemid 23292617)
49. Oudijk EJ, Nijhuis EH, Zwank MD, et al. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005; 60: 538-544. (Pubitemid 40966205)
50. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000; 55: 603-613.
51. Huang S, Hershey JW. Translational initiation factor expression and ribosomal protein gene expression are repressed coordinately but by different mechanisms in murine lymphosarcoma cells treated with glucocorticoids. Mol Cell Biol 1989; 9: 3679-3684. (Pubitemid 19216262)
52. Casini-Raggi V, Kam L, Chong YJ, et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434-2440.
53. Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 644-652. (Pubitemid 24145067)
54. Sapey E, Ahmad A, Bayley D, et al. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 2009; 29: 508-516.
55. Rupp J, Kothe H, Mueller A, et al. Imbalanced secretion of IL-1β and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J 2003; 22: 274-279. (Pubitemid 36986997)
56. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-2444.
57. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-2437.
58. Arend WP, Welgus HG, Thompson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694-1697. (Pubitemid 20176469)
59. Granowitz EV, Clark BD, Mancilla J, et al. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147-14150. (Pubitemid 21907472)
60. Koch B, Lemmermeier P, Gause A, et al. Demonstration of interleukin-1β and interleukin-6 in cells of synovial fluids by flow cytometry. Eur J Med Res 1996; 1: 244-248.
61. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-1359. (Pubitemid 40664079)
62. Bresnihan B. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2002; 61: Suppl. 2, ii74-ii77.
63. Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis 2008; 67: 281-282. (Pubitemid 351281258)
64. Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20: 319-325. (Pubitemid 38388233)
65. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581-592. (Pubitemid 44200651)
66. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006; 25: 6887-6899. (Pubitemid 44657858)